Polio [strain Sabin] vaccine is under clinical development by Panacea Biotec and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Polio [strain Sabin] vaccine’s likelihood of approval (LoA) and phase transition for Poliomyelitis took place on 28 May 2021, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Polio [strain Sabin] vaccine Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Polio [strain Sabin] vaccine overview
Vaccine candidate is under development for the prevention of poliomyelitis. The vaccine candidate is formulated as a suspension and administered through intramuscular and intradermal routes. It is a sabin inactivated polio vaccine.
Panacea Biotec overview
Panacea Biotec (Panacea) is a research-based health management company that research, develops, manufactures, distributes and markets pharmaceuticals, vaccines and biosimilars. Its vaccines portfolio includes trivalent and bivalent oral polio vaccine, and vaccines for diphtheria, tetanus, pertussis, Hepatitis B and haemophilus influenzae Type B. Its pharmaceutical formulations span across therapeutic areas, including oncology, nephrology, orthopedics, gastroenterology, pain management, diabetes, blood related, and organ transplantation, among others. The company also offers contract research and manufacturing services. Panacea operates manufacturing facilities in Baddi, Himachal Pradesh and Lalru, Punjab. It has presence in India, Switzerland, and Germany. Panacea is headquartered in New Delhi, India.
Quick View Polio [strain Sabin] vaccine LOA Data
|Highest Development Stage|